CD274 and melanoma: Our results demonstrate for the first time that a peripheral blood-derived biomarker (PD-L1+ PMN frequency) could independently predict patient clinical outcome to nivolumab in BRAF wild type melanoma patients, providing an additional tool for therapeutic choices in clinical oncology.